SEARCH FOR SCI CURE: clinical trial now enrolling quadriplegics with aim of restoring function of arms and hands

ReNetX Bio announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track Designation for its AXER-204 clinical therapy for the potential treatment of quadriplegics with a chronic cervical spinal cord injury. AXER-204 is a human fusion protein that acts as a soluble decoy/trap for the myelin-associated inhibitors of axonal growth known as Nogo-A, MAG, and OMgp. AXER-204 and a surrogate protein used in early preclinical studies have been found to promote axon growth and recovery of function in animal models of spinal cord injury.

The Phase 2 clinical trials involve a multicenter, randomized, double-blind, placebo-controlled, repeat dose study in chronic cervical spinal cord injury participants. Up to 42 participants will be randomized (ratio 1:1) to receive repeated doses of AXER-204 or placebo (a phosphate buffered saline formulation). The trials are taking place in California, Ohio, Illinois, Pennsylvania and Georgia.

You can get complete details about this trial HERE.